Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.20 -2.25% 8.675 271,264 14:16:35
Bid Price Offer Price High Price Low Price Open Price
8.35 9.00 8.875 8.625 8.875
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.11 -4.10 -3.47 9
Last Trade Time Trade Type Trade Size Trade Price Currency
16:14:21 O 1,821,664 8.15 GBX

Synairgen (SNG) Latest News (1)

More Synairgen News
Synairgen Takeover Rumours

Synairgen (SNG) Share Charts

1 Year Synairgen Chart

1 Year Synairgen Chart

1 Month Synairgen Chart

1 Month Synairgen Chart

Intraday Synairgen Chart

Intraday Synairgen Chart

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date Time Title Posts
17/10/201916:32Synairgen - a cure for Asthma?1,111
19/10/201008:22Synairgen - Blockbusting potential50
17/3/201018:34Canadian Superior Energy: No.American Gas&Oil8

Add a New Thread

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-17 16:15:008.151,821,664148,465.62O
2019-10-17 15:14:238.6557,7574,995.98O
2019-10-17 15:08:118.4150,0004,205.00O
2019-10-17 15:05:358.7010,000870.00O
2019-10-17 15:01:588.7010,000870.00O
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 8.88p.
Synairgen Plc has a 4 week average price of 7.75p and a 12 week average price of 7.75p.
The 1 year high share price is 18.50p while the 1 year low share price is currently 7.75p.
There are currently 109,433,442 shares in issue and the average daily traded volume is 752,626 shares. The market capitalisation of Synairgen Plc is £9,493,351.09.
rosejs2: A possible smart move by the 'Executors' of Woodfords Trust.. Transferring ownership to Blackrock.. Why? The value contained within SNG and its current lowly share price do not reflect anywhere near its true value and as 'Luzley' above states: current indications are positive on Interferon B.. therefore my conclusion (for what it is worth) either Blackrock are prepared to take them on their own books as a 'speculative' investment or even more cleverly they might instigate an auction for their new SNG Holding at a substantially higher price, AZN take note !!
rosejs2: From memory The majority of Woodfords SNG holding is in his Equity Income Fund (even though SNG has never paid any Dividend).. If there is a positive from the Woodford demise .. I suspect a number of organisations including both financial / Pharma / others will be assessing the likelihood of success of Interferon B and the value of SNG's stake in LOXL2 … The 20% plus of Woodfords holding in SNG cannot (in my opinion) just be sold through the market .. small sales tend to crash the SNG share price .. The significant stake will I believe find a new home where the value of the current portfolio can be appreciated, nurtured and monetised.. e.g. AZT or similar or an Investment Trust that focus's on Bio/Pharma investments. The elimination of the Woodford SNG overhang on the shares should see the real value of SNG shares emerge..
pdt: I noticed on another board that a poster had noted that the Pharmaxis share price jumped 20% last night. Is news imminent? Either news on a LOXL2 deal or Boehringer trial news. Hopefully, the former as a Synairgen shareholder :)
rambutan2: Well well well, Woodford reduces...
timbo003: Synairgen (SNG) 2019 AGM report The Synairgen 2019 AGM was held on Monday 3rd June at the offices of Fladgate LLP, 16 Great Queen Street, London. For anyone who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at 130p/share valuing the company at around £28m. There have been several placings since the IPO; the most recent was in Sept 2018 to raise £2.9 million through the issue of around 18M ordinary Shares at a price of 16p/share (a discount of around 11%). The shares currently trade at around 13p/share valuing Synairgen at about £14m. The company broker Finncap currently have a price target of 54p/share based on a sum-of-the parts DCF, comprising c.39p/share for SNG001 and 15p/share for Pharmaxis’s LOXL2 inhibitors, in which Synairgen has a 17% economic interest Synairgen has two main assets in clinical development, the principle asset is SNG001 (inhaled beta-interferon) which is currently undergoing evaluation in a Phase II study to treat exacerbations associated with respiratory virus infections in patients with COPD. SNG001 has previously been studied in two separate Phase II studies to treat exacerbations in asthma patients with mixed success. Post hoc analysis of the results lead to the conclusion that in order for SNG001 to be effective, the exacerbation should be associated with a respiratory virus infection, therefore the presence of a viral respiratory infection is a stipulated requirement for patient entry into the current COPD study. Synairgen’s second asset is a shared interest in a Lysyl Oxidase Like homologue 2 (LOX2) program with Pharmaxis, a pharma company quoted on the Australian stock exchange (ASX: PXS) with a market cap of around £60m. LOXL2 inhibitors have shown the ability to prevent fibrosis in animal models and they should find utility in treating a range of fibrotic and pre-fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF) and Fatty liver disease, otherwise known as Non-alcoholic steatohepatitis (NASH). There are currently 2 lead compounds from the LOXL2 program (PXS-5382 and PXS-5338) which are Phase II ready, with Pharmaxis currently conducting commercial partnering discussions with numerous large pharma companies. According to the latest available Pharmaxis investor slide deck (April 2019) and a recent Proactiveinvestor interview with the CEO (May 2019) the company hope to concluded partnering discussions during H1 2019 or Middle of the year. Synairgen are due to receive 17% of any up-front and milestone payments and 17% of any royalties received by Pharmaxis, furthermore there is no requirement for Synairgen to pay any further costs towards the development of the LOXL2 compounds. Links to last year’s AGM report, the Synairgen Web site, Annual Report and other useful information are given below: 2018 AGM report: Web site: 2019 Annual Report: Latest presentation slide deck (Feb 2019): Finncap broker notes: Formal Business There were around 15 attendees at this year’s meeting, including the BOD and representatives from the Registrar, Company Solicitor, PR representatives and the Company Broker. I was the only private shareholder present. The Chairman (Simon Shaw) told the meeting that all the directors were up for re-election this year as they had all served on the BOD for 9 years or more. I asked whether there had been any pressure to do this from large shareholders, or from ISS (Institutional Shareholder Services) who advise institutions how to vote on corporate governance resolutions. I was told that there were no such requests. All the resolutions were passed unanimously on a show of hands and the proxy votes showed large majorities in favour of all the resolutions. Q&As then followed which went on for around 30 minutes. Q&As (Note: these Q&As are paraphrased, they are not a verbatim account) LOXL2 program Q: On the LOXL2 program, what happens if Pharmaxis decide to go it alone with one or both of the LOXL2 compounds rather than out-licence to a Big Pharma partner? A: Synairgen will still get 17% of all revenue. They would forgo certain milestone payments, but longer term revenue from sales would be higher as a result. Q: Do the BOD have any preference regarding whether Pharmaxis partner now, at a later stage, or go it alone? (I had to ask this several different ways to get any sort of an answer) A: Our preference is for Pharmaxis to take whatever route gives the best long term outcome for Synaigen shareholders. Q: If Pharmaxis were to delay partnering to a later stage, or to go it alone, surely this would have an impact on the timing and quantum of Synairgen’s next funding round, so with the current lowly share price wouldn’t be in Synairgen shareholders best interest for Pharmaxis to partner early, so triggering an upfront payment to Synairgen? A: The BOD are currently focused on the COPD trial and events where they have can have some control and in particular the recruitment rate for the ongoing COPD study with SNG001. Q: Pharmaxis currently have two LOXL2 compounds which are Phase II ready and deal ready. Is there any reason to believe that one of these compounds may be more suited to NASH and the other to IPF? Or have they just developed two compounds so they can do a deal with two separate pharma companies to enable a better overall deal? A: That is a question for Pharmaxis, they own the compounds. There may be information on their web site about this. We do not have a view. (My comment: they almost certainly do have a view, but not one they are prepared to air publicly) Q: Which of the two LOXL2 indications do you consider to be the largest opportunity? A: We consider them both to be substantial opportunities (i.e. peak sales of >$ 1bn/annum) Q: I have asked before about the competition for IPF and LOXL2, has anything changed recently? A: There are two recently approved (expensive) drugs for IPF which are doing well from a commercial perspective (pirfenidone and nintedanib). Both drugs slow down disease progression, but they have not been shown to improve mortality. Neither of these two drugs have any anti-fibrotic properties. For NASH there are a couple of drugs that have reached the phase IIb stage, but they are not LOXL2 inhibitors. SNG001 for COPD Q: You mentioned that the cold/flu season had been mild this season, how mild is it and are you considering expanding the study to the southern hemisphere if recruitment rate is too slow here? A: It is less severe this season than last season and it got off to a slow start, the SNG001 study is being run in the UK, there are no plans to expand the study abroad. Q: Are infection rates picking up or do you expect them to pick up? A: There are regular reports available on cold/flu infection rates from Public Health England, we will send you the link: The recent introduction of the Biofire Filmarray has been of paramount importance for recruitment, so only patients with confirmed viral infections are recruited into the study. Not only does it confirm the presence of pathogens, it will also distinguish between bacteria and virus infections and between different viruses. Q: Should investors feel at all concerned about Faron’s unfortunate finding that steroids adversely affect the efficacy of beta interferon (Traumakine) in ARDs patients, given that many COPD patients are also likely to be on steroids? A: Absolutely not, it is a completely different mechanism Q: Would you expect beta interferon administered SC (betaferon) or IV (traumakine) to be effective in COPD patients with respiratory disease? A: No, there wouldn’t be enough drug getting to the lungs which is where the main battle against the virus takes place. Furthermore, the drug has quite a low therapeutic window, so increasing the dose significantly would not be an option. Pipeline: Q: What else are you looking at regarding the future Pipeline? A: One big opportunity would be to extend the use of SNG beyond COPD patients (or asthmatics). Some groups of patients are particularly vulnerable to respiratory tract viral infections, for example diabetics and patients with some CNS disorders (for example stroke). There are many diabetics who present at A&E with difficulty breathing as a result of a respiratory tract viral infection and there is currently not much you can do for them. The only drug treatments available are Tamiflu and Relenza, but neither is particularly effective. Q: Is there a reason to believe that you could use the LOXL2 inhibitors for cystic fibrosis, given that LOXL2 inhibitors are anti-fibrotic? A: No, cystic fibrosis is a bit of a misnomer as there is no fibrosis present in CF. Q: Is there a reason to believe that you could use SNG001 for respiratory viral infections for cystic fibrosis? A: Yes Recommended reading: Tamiflu and Relenza review questions effectiveness against flu (2014) Infections in patients with diabetes mellitus: A review of pathogenesis (2012) Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus (2005)
ohisay: I was just checking back to see the implied market cap of the SNG share price when AZN farmed into SNG001 in 2014. On the morning of the deal the share price ran up to 70p/75p but there were 78m shares in issue then; so adjusting for the current 110m would equate to 50p+ per share. SNG were a one trick pony at the time - they didnt have the LOXL2 upside then - so throughout the AZN asthma trial the price slipped back to under 40p. If the current ability to do cheap trials on COPD had been available to AZN after the inconclusive asthma results (through the novel point of care diagnostic tool) I doubt they would have handed back SNG001 to SNG. So if the SNG COPD phase 2 trial here is successful in Q2 its not beyond the bounds of possibility AZN could be back to finance a phase 2B .Marsden has said as much and with a trial size of 190 patients up from the original 120 it isnt as if they wont have substantive data in front of them. The numbers Finncap are ultimately talking about in that case are not wildly different to that 2014 deal; COPD is still a largely unmet clinical need after all. Idle musings perhaps... [More interim news next month.03/15/19 2018 Earnings Release (Projected)]
ohisay: Indeed .COPD safety study due first I think. Worth recalling the House broker view ... Broker FinnCap reckons the stock is worth 35p based on a discounted cash flow (DCF) valuation that that puts 17p and 18p a share price tags on, respectively, SNG001 and LOXL2. This DCF valuation will rise to £41mln, or 45p a share following the successful completion of a pilot safety study of SNG001
rosejs2: Nobby... You are not talking to yourself.. I agree with all of your points.. SNG is a unique share... the 17% of Pharmaxis LOXL2 offers huge opportunity .. with an expected upfront payment to Pharmaxis of up to $50m (if the Phase 1 trials prove successful) and further signifcant stage payments on its journey to commercialisation. The Income coffers of SNG COULD soon be flush with substantial additional funds.. With the commencement of Phase 2 Trials on SNGs own Interferon B now underway... with initial results in Q2 2018...There cannot be a share as unique as SNG to hold.. No debt, enough cash rerserves topped up by the recent £5m payment from Pharmaxis achieving full control of the LOXL2 programme .. It is a share to watch, hold and wait for information that can and might lead to many multiples of its current share price.. IMHO.
rosejs2: ohisay ... I do agree with your sentiments.. Here we have a company with NO debt, £5m to come from Pharmaxis, 17% of future revenues from LOXL2 Developments (these could be huge if the Phase 1 trials meet expectations and the right partners found)... Approx £2m in current cash... Alongside progression of SNG001 into COPD, What is there not to like.. If you look at the Major shareholders 5 of which including Woodford Investment Management own approx 64% of the issued equity...only 91.36 million shares... Both areas of development LOXL2 and COPD are if successfull worth Billions to major Pharma Partners... whilst the 'IF' is speculative.. the quality of both Management and Scientific Expertise in both Pharmaxis and SNG is second to none.. Why is the share price falling ? my view for what it is worth is that SNG shares are quite illiquid small sales or purchases can move the price one way or the other .. and currently some small sells are driving the price down.. It may on the other hand be a tree shaking exercise by the market makers who require stock to meet their obligations.. and hitting individual stop losses may be the only way to obtain stock... but that is just my speculation.. 2018 will be a very exciting year for SNG for both LOXL2 and progress on COPD ... If SNG management can supply regular updates on progress, the market should become more aware of the real potential of SNG and its revenue streams. The market should then respond positively in raising SNG shares substantially above its current lowly Price..
wookie77: Thanks Ohisay........If SNG share price can get above the 40p neck line then we really are off to the races IMO.
Synairgen share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191017 23:50:42